Bevacizumab increases visual acuity in ocular melanoma patients treated with plaque radiotherapy

PHILADELPHIA — Ocular melanoma patients who received prophylactic bevacizumab with plaque radiotherapy experienced significantly better visual acuity outcomes than control patients who did not receive bevacizumab, according to a speaker here.
“The complications of plaque radiotherapy are numerous, including retinopathy, papillopathy, choroidopathy and others,” Carol L. Shields, MD, said at the Wills Eye Conference. “So, how can we prevent or maybe eliminate these complications?”
Previous studies showed that one injection of an anti-VEGF agent did not change visual

Full Story →